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Here, we describe two insights into the role of receptor conforma-
tional dynamics during agonist release (all-trans retinal, ATR) from
the visual G protein-coupled receptor (GPCR) rhodopsin. First, we
show that, after light activation, ATR can continually release and
rebind to any receptor remaining in an active-like conformation. As
with other GPCRs, we observe that this equilibrium can be shifted by
either promoting the active-like population or increasing the agonist
concentration. Second, we find that during decay of the signaling
state an active-like, yet empty, receptor conformation can transiently
persist after retinal release, before the receptor ultimately collapses
into an inactive conformation. The latter conclusion is based on time-
resolved, site-directed fluorescence labeling experiments that show a
small, but reproducible, lag between the retinal leaving the protein
and return of transmembrane helix 6 (TM6) to the inactive conforma-
tion, as determined from tryptophan-induced quenching studies. Ac-
celerating Schiff base hydrolysis and subsequent ATR dissociation,
either by addition of hydroxylamine or introduction of mutations,
further increased the time lag between ATR release and TM6 move-
ment. These observations show that rhodopsin can bind its agonist in
equilibrium like a traditional GPCR, provide evidence that an active
GPCR conformation can persist even after agonist release, and raise
the possibility of targeting this key photoreceptor protein by tradi-
tional pharmaceutical-based treatments.
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The superfamily of G protein-coupled receptors (GPCRs) isone of the largest targets of pharmaceutical drugs in the
human genome. Classically, GPCR signaling occurs when a dif-
fusible ligand (such as a drug) binds to the receptor and stabilizes
conformations that can couple with and activate intracellular
proteins. Our understanding of this process has built on the
classical “ternary complex” model of receptor–ligand–G protein
interaction (1), a model that, with revisions, has continued to
guide our knowledge of how this critical event occurs.
However, this paradigm has faced problems when applied to
rhodopsin, the dim-light visual receptor. Rhodopsin is kept in an “off”
state by a covalently bound inverse agonist, 11-cis retinal (11CR).
Light converts the 11CR to an agonist, all-trans retinal (ATR), which
enables the receptor to activate its G protein, transducin (Gt) (2, 3).
The active receptor, metarhodopsin II (MII), continues signaling until
the Schiff base linking ATR to the receptor is hydrolyzed, resulting in
the release of ATR and the decay of MII into an inactive apoprotein,
opsin (4, 5). Binding of a new 11CR to opsin reforms the dark state
(DS), enabling another round of photon detection (6).
Due to this unusual light-activated, covalently bound ligand,
rhodopsin has usually been considered “different” from the
larger superfamily of diffusible ligand-binding GPCRs. However,
we recently discovered that rhodopsin behaves more like a tra-
ditional ligand-binding GPCR than previously thought (7). Our
experiments found that inactive receptor (Ops) preferentially
binds inverse agonist (11CR), whereas active-state receptor
(Ops*) binds agonist (ATR) (8). We proposed these results in-
dicate that retinal–opsin interactions are governed by the same type
of a conformational selection model proposed for other GPCRs
(Fig. 1) (9).
This model challenges some long-held assumptions about retinal
binding, predicts some unexpected behavior, and contains two
testable hypotheses. First, it suggests that, after release, ATR can
rebind any receptors remaining in an Ops* conformation (Fig. 1, i).
This is in contrast to current assumptions that ATR release is ir-
reversible after Schiff base hydrolysis and directly reflects the decay
of the active MII species (10, 11). The second idea builds on the
first—if ATR rebinding requires an active-like Ops* conformation,
then an active Ops* state may persist after ATR release (Fig. 1, ii).
Here we directly tested both hypotheses. First, we measured
ATR release for samples containing different amounts of active
opsins and found that the extent of ATR “release” inversely
correlates to the amount of Ops* present—the more Ops*, the
less free ATR. Using fluorescence assays and radioligand bind-
ing studies, we established this occurs because during MII decay
ATR release and rebinding are in equilibrium.
Second, we tested whether any active Ops* conformers can
persist after ATR release by simultaneously measuring ATR in the
receptor and the conformational state of the receptor in real time.
Our results show that ATR release and the reversion of Ops* to the
inactive conformation occur sequentially, but not always simulta-
neously. The observation that an active-like Ops* state can exist
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even after agonist release may have wider implications for other
GPCRs, and our finding that rhodopsin can bind its agonist ATR in
equilibrium opens the possibility of using classical pharmacological
methods to both study and ultimately target this key photoreceptor.
Results
Stabilization of Ops* Prevents Full Retinal Release. A conforma-
tional selection model (Fig. 1) predicts that, after release, ATR
will rebind to any receptor remaining in an active (Ops*) con-
formation. We tested this idea using opsin samples with varying
amounts of active Ops*, monitoring the protein fluorescence
increase that occurs as retinal dissociates (10).
For light-activated WT rhodopsin (11CR-bound receptor), these
assays show that ATR release is complete—tryptophan fluores-
cence increases and ultimately reaches a plateau that does not
increase when hydroxylamine (HA) is added to convert ATR to
ATR-oxime (which does not rebind opsin), as well as to cleave any
remaining retinal–Schiff base attachments (Fig. 2B) (10, 12, 13).
In contrast, rhodopsin samples that contain active Ops* due to
a constitutively activating mutation M257Y (CAM) (14, 15) do
not show full ATR release. Instead, ∼60% of the CAMs have
ATR still bound under steady-state conditions (Fig. 2C) and thus
show a large fluorescence increase upon HA addition.
Even more dramatic results are observed for rhodopsin samples
that have a high-affinity analog of the Gtα C terminus fused to
their end (GtF) (8), which stabilizes the active Ops* conformation.
After light activation, these samples show almost no apparent
ATR release. All rate values and percent ATR retention for Fig. 2
are reported in Table 1.
Equilibrium Binding Explains the Lack of Apparent ATR Release for
Ops*-Containing Samples in the Retinal Release Assays. Two possi-
bilities could explain the results above. Either release is blocked in
the samples with more Ops* or ATR is continually releasing and
rebinding in equilibrium to the stabilized active receptors. To de-
termine which is correct, we exploited a key difference between these
two scenarios: Retinals involved in equilibrium binding would be-
come exposed to bulk solvent, whereas trapped retinals would not.
Thus, we repeated the ATR release assays in the presence of
o-tert-butyl HA (tbHA). An alkylated derivative of HA, tbHA is
too big to enter the receptor binding pocket and therefore can
only react with retinals that have dissociated (16). As expected,
tbHA did not affect WT rhodopsin (compare Fig. 2 E and B).
However, tbHA caused complete ATR release for the CAM
sample (Fig. 2F) and even induced ATR release from GtF, al-
though at a slower pace, presumably because some ATR rebinds
to Ops* faster than it can collide and react with tbHA (Fig. 2G).
These results suggest the apparent incomplete release is due
to ATR leaving and rebinding the receptor, rather than being
“trapped” inside the binding pocket. Consistent with this in-
terpretation, we found the amount of ATR bound to the CAM
increased with increasing amounts of exogenous ATR (Fig. 2I),
as would be expected for equilibrium binding. Intriguingly, at
higher ATR concentrations even WT opsin showed increased
binding (Fig. 2H), suggesting this phenomenon is not exclusive to
mutants with increased Ops* populations. As expected, the ATR
release profile for GtF shows no change with extra ATR, because
the receptor is already fully bound with ligand (Fig. 2J).
Radioactive Ligand-Binding Studies Further Confirm an ATR-Binding
Equilibrium Can Occur After Receptor Photoactivation.We next tested
whether ATR could bind in equilibrium by monitoring ex-
change of ATR produced inside the protein by light with exoge-
nously added radioactive ATR (Fig. 3A). In these experiments,
we added an equimolar amount of [3H]ATR to each sample
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Fig. 1. Conformational selection model for retinal binding to opsin (8). The
focus of the current work is on the process of ATR dissociation from opsin
(enclosed in the dashed rounded rectangle) testing two hypotheses: first,
that ATR will bind in equilibrium depending on the conformation of the
opsin (i), and second, that the reversion of Ops* to Ops is distinct from the
ligands presence, resulting in the possibility of an active Ops* state can
transiently persist in the absence of ligand (ii).
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Fig. 2. Evidence that ATR released during decay of photoactivated MII
rhodopsin can rebind in an Ops*-dependent manner. (A) Cartoon depiction
of how retinal release following light activation can be monitored by an
increase in intrinsic protein fluorescence. (B) Release trace from WT opsin
shows a monoexpontential rise to a plateau. HA treatment yields no addi-
tional release, indicating full ATR dissociation. (C) Release from the CAM
instead results in some ATR remaining bound to the receptor in an equi-
librium that is only relieved when HA is added. (D) Photoactivation of GtF, a
rhodopsin sample with the Gtα C terminus fused on its end, shows no ap-
parent ATR release until HA is added. (E) Addition of tbHA, an HA derivative
that cannot enter the binding pocket (16), had no effect on retinal release
for the WT sample (compare with B). (F) In contrast, tbHA induces full retinal
release from the CAM, resulting in data nearly identical to the WT opsin.
(G) Similarly, the presence of tbHA induced a (slower) retinal release from
GtF. Subsequent assays measured in the presence of increasing amounts of
added ATR show a shift in the equilibrium to more bound ATR. (H) Results
for increasing [ATR] for WT rhodopsin release. (I) Extra ATR further shifts the
CAM toward the bound state. (J) Experiments with GtF and increasing
amounts of ATR show no change, because the receptor is already fully
bound at the lowest ATR concentration. Release experiments were con-
ducted at 20 °C in 0.05% N-dodecyl-β-D-maltopyranoside (DDM) at pH 6.0.
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then measured how much of it had bound to the receptors after
light activation. As shown in Fig. 3B, the amount of receptor-
bound [3H]ATR mirrored the amount of active Ops* present in
the samples (Fig. 3B).
Expanding on this result, we tested how fast the exchange could
occur for the GtF rhodopsin sample. On the surface, the GtF
rhodopsin samples seem to have a stably bound ATR after light
activation—they show no apparent ATR release in the fluores-
cence retinal release assay (Fig. 2D), and they have a stable Schiff
base linkage as determined by acid protonation (Fig. 3D). How-
ever, within minutes after light activation, these samples show full
exchange with exogenously added [3H]ATR (Fig. 3C). Interest-
ingly, the receptors show complete expected exchange (calcu-
lated from the expected maximal binding, Fig. S1) that occurs
even faster than retinal release from the WT protein (t½ GtF
exchange of ∼5min vs. t½ WT ATR release of ∼13 min).
Method for Simultaneously Measuring Retinal Release and the Conversion
from Active Ops* to Inactive Ops Conformation. Along with equilibrium
binding, the conformational selection model predicts another unusual
possibility: that an active-like Ops* conformation can persist follow-
ing the release of bound agonist (Fig. 1, ii). We tested this hypothesis
by modifying the retinal release assay to simultaneously monitor the
receptor conformational state and ATR release (described above).
The Ops* state was monitored by tracking the large movement of
transmembrane helix 6 (TM6) that occurs during receptor activa-
tion, using the Trp-induced quenching (TrIQ) technique (17). TrIQ
monitors the quenching of the small fluorescent probe bimane, which
only occurs when the Trp and probe are in near contact (18).
Specifically, we attached a bimane to a cysteine on the cyto-
plasmic end of TM6 (V250C) and introduced a Trp across from it
on TM3 (V139W). Previous studies of rhodopsin (19) and the β2
adrenergic receptor (B2AR) (20) have shown activation moves this
pair into close contact, resulting in a large decrease in probe
fluorescence (see Fig. 4A, Ops*). During decay of MII, TM6 moves
back to its starting, inactive position, resulting in a fluorescence
increase as the bimane quenching is relieved (Fig. 4A, Ops).
Importantly, the absorbance spectra are essentially identical
for the V139W/V250B and the V250B control sample. Both
show complete conversion to active MII rhodopsin (indicated by
the shift from 500-nm to 380-nm absorbance) and no optical
artifacts that could affect direct comparison of their fluorescence
properties (Fig. 4 B and C).
However, their fluorescence emission spectra are strikingly
different. For the control, V250B, the bimane fluorescence in-
creases immediately after photoactivation to a maximal value
and stays constant (Fig. 4 D and F). This increase is caused by the
500- to 380-nm shift in retinal absorbance, which removes FRET
from the bimane to 11CR in DS rhodopsin (21). In contrast, the
V139W/V250B fluorescence does not increase immediately after
photoactivation. Rather, it slowly grows with a rate closely match-
ing the profile of retinal release (Fig. 4 E and G), as the probe on
TM6 moves close to (and is quenched by) the Trp on TM3 during
MII formation (19, 20), then over time returns to its initial inactive
position, relieving the TrIQ (19–21).
ATR Dissociation and the Conformational Change from Ops* to Ops Do
Not Always Occur Simultaneously. Although TM6 movement and
ATR release seem to coincide for the WT (V139W/V250B) rho-
dopsin (Fig. 4G), a closer examination reveals a short, but re-
producible, delay between the events (Fig. 5A). To see whether this
lag was real, and could be increased, we repeated these experiments
under conditions that accelerate ATR dissociation. Two different
approaches were used. First, we carried out the experiments in
the presence of HA (Fig. 5C) to cleave the retinal–Schiff base
linkages immediately after photoactivation (10). As expected,
HA treatment dramatically increases the rate of ATR release.
However, although TM6 movement was also accelerated in the
presence of HA (Fig. 5C), it was noticeably delayed in com-
parison with ATR release.
We also tried decoupling ATR release and TM6 movement by
introducing a mutation that promotes ATR dissociation. The muta-
tion, A295S, lies immediately next to the Schiff base lysine at position
296 and greatly increases retinal release rates (22). Indeed, TM6
movement for A295S, although also accelerated, substantially lags
behind ATR release (Fig. 5E). Together, these results support the
model in Fig. 1 suggesting that retinal release and conversion of Ops*
to Ops are sequential, yet distinct, events, with an active-like Ops*
conformation transiently persisting after retinal release. All of these
experiments were repeated at different temperatures, and the nearly
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Fig. 3. ATR produced inside rhodopsin by light bleaching can exchange with
an equimolar amount of exogenously added, radioactive [3H]ATR. (A) Cartoon
depiction of the ATR exchange experiments. (B) The amount of radioligand
exchange for WT, CAM, and GtF rhodopsins at 2 h after photoactivation
correlates with the amount of active Ops* and retinal trapping seen in
Fig. 2. (C) Time-course measurement for the GtF construct shows complete and
rapid ATR exchange (t½ ∼4.7 min). (D) Surprisingly, although GtF clearly shows
exchange with exogenous [3H]ATR, acid protonation experiments of identical
samples show that the light-activated ATR–Schiff base linkage in GtF remains
“stable” for the entire (2-h) length of the exchange experiment [note the ∼440-nm
absorbing species indicating a protonated retinal Schiff base (PSB)]. Experiments
were performed at room temperature in 0.05% DDM at pH 6.0.
Table 1. Time to half-maximal ATR release and percent remaining complexes before HA addition
+0.0 μM ATR† +0.5 μM ATR +2.0 μM ATR +tbHA‡
Sample t½, min % Bound t½, min % Bound t½, min % Bound t½, min % Bound
WT§ 12.5 ± 1.0{ 4.63 ± 0.78 10.9 ± 0.52 12.1 ± 2.2 7.17 ± 0.10 30.4 ± 5.8 10.0 ± 2.3 −0.03 ± 2.1
CAM 3.26 ± 0.37 62.5 ± 3.1 n.d.# 85.6 ± 1.4 n.d. 96.0 ± 3.1 11.2 ± 0.5 2.76 ± 1.0
GtF n.d. 103 ± 4.3 n.d. 104 ± 1.4 n.d. 107 ± 0.38 24.9 ± 0.97 23.0 ± 4.2
†Exongenous ATR was added before photoactivation.
‡Ten millimolar tbHA was added before photoactivation.
§All experiments at 20 °C, 0.5 μM 11CR incubated overnight with 0.75 μM opsin.
{Errors reported are SDs.
#Not determined (n.d.); rates of release from experiments showing too little initial release for a reliable fit are not reported.
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identical results from Arrhenius analyses suggest that the underlying
mechanism involved is not altered by either the introduced chemical
(HA) or mutation (A295S) (Fig. 5 B, D, and F). Other mutations
known to impair G protein interaction [Y223A,F (23, 24)] were also
investigated and showed a similar delay (Fig. S2). Table S1 reports the
retinal release rates and Arrhenius values for the tested conditions.
Discussion
In the present work, we tested two questions concerning retinal–
rhodopsin interactions: Can ATR released from activated rhodopsin
rebind to the receptor, and can an empty, yet active, receptor con-
formation (Ops*) transiently persist after ATR is released? Our
results and their implications are discussed below.
After Rhodopsin Photoactivation, an Equilibrium of ATR Release and
Rebinding Can Occur If Ops* Is Present. Binding of either Gt or
arrestin can cause incomplete ATR release from photoactivated
rhodopsin (12, 25). The presumption has been that the retinal
release is blocked, causing the ATR to be “trapped” inside the
receptor binding pocket (12, 13). However, our results with the
CAM, M257Y, made us rethink what actually causes retinal
“trapping.” Similar to release in the presence of Gt or arrestin,
the CAM does not show complete retinal release, but instead
reaches an initial plateau that persists until HA is added. Based
on this result, we asked whether the phenomenon of retinal
“trapping” could in some cases actually be caused by ATR re-
leasing and rebinding in equilibrium.
We first tested this idea using the HA derivative tbHA. Like HA,
tbHA reacts with ATR to form retinal-oxime that cannot rebind to
the receptor. However, because tbHA is too large to enter the
ligand-binding pocket (16), and thus can only modify ATR that has
exited the protein, retinal release would only be affected if release
and rebinding is occurring. In agreement with previous observa-
tions, tbHA has little effect on the release of ATR from WT
rhodopsin (Fig. 2E) (16). However, for the CAM, tbHA completely
abolished the initial incomplete release (Fig. 2F), and even greatly
increased the rate of ATR release from the GtF sample (Fig. 2G).
Clearly, these results suggest retinal “trapping” is actually
due to an equilibrium of ATR release and rebinding for both
the CAM and the GtF. What could cause this equilibrium? A
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initial increase is absent, and instead the emission only slowly increases over time.
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likely explanation is that the ATR is in flux between the active
and inactive opsin populations present in both mutant samples.
Thus, in samples where the completely inactive Ops state is fa-
vored (WT), ATR seems to fully release (Fig. 2B). In contrast,
when an active conformation is stabilized, such as the CAM, an
intermediate plateau is observed (Fig. 2C). For GtF (the sample
with the most Ops*) ATR release seems blocked (Fig. 2D).
Our radioligand binding experiments further confirm retinal
release–rebinding equilibrium is occurring. The ATR produced
inside the receptor (by light activation) clearly exchanges with
externally added, radioactively tagged [3H]ATR (Fig. 3), with the
amount of exchange correlating with the amount of stabilized
Ops* present (Fig. 3B).
The most striking example is seen for the GtF sample. ATR
seems to be fully “trapped” in GtF by the fluorescence retinal
release assay (Fig. 2D). However, the ATR produced in GtF by
light activation rapidly exchanges with externally added [3H]ATR
with full exchange achieved within minutes (Fig. 3C). Thus, ATR
only seems to be “fully bound” because, under steady-state con-
ditions, most of the ATR is bound to receptors in Ops* confor-
mation—the “stable” Schiff base linkage attaching ATR to GtF is
actually rapidly breaking and reforming as the retinal releases and
rebinds the receptor (discussed below).
In retrospect, our results are perhaps not so surprising. Several
groups have shown a dose response for ATR-induced G protein
activation and arrestin binding (26, 27), and the ability of ATR to
bind to active-stabilized opsins has also been shown (8, 14, 28–30).
Our results with WT protein (Fig. 2H) suggest that this ability is
not unique to mutants with stabilized Ops* but is a property in-
herent to opsin, dependent only on relative agonist concentration.
How other rhodopsin photoproducts, metarhodopsin I and III,
might affect the binding equilibrium is not clear, because our
detergent-purified system favors MII formation (Fig. 3D). How-
ever, although this process may be more complicated in native rod
cells, the fundamental conclusions should not change.
Is “Retinal Release” Due to the Protein’s Reverting Back to an Inactive
Ops Conformation Faster Than the Released ATR Can Rebind? Our
results show that the extent of apparent ATR release depends on the
amount of Ops* present. What insights does this give about the
mechanism underlying ATR dissociation? One intriguing possibility
is that “release” simply reflects the protein’s inability to rebind the
ATR agonist—when the Ops* conformation is stabilized, more ATR
binding is observed in the fluorescence release assay (10, 12, 22).
This interpretation also raises the possibility that ATR could be
in flux from the moment of photoactivation, as suggested by the
rapid exchange with exogenously added [3H]ATR seen in GtF
(Fig. 3C). If ATR can exchange much more frequently than pre-
viously thought, then it may be possible to outcompete the
rebinding of ATR with drugs designed to either temper the ac-
tivity of rhodopsin after light exposure, or alternatively, encourage
ATR dissociation from hyperactive rhodopsin mutants and thus
enable regeneration with 11CR and proper photocycling.
These results also suggest interesting implications about the
instability of the covalent Schiff base linkage. Previously, we pos-
tulated that the Schiff base connecting the 11CR to the dark-state
protein may spontaneously hydrolyze but then rapidly rebind to
the receptor due to a “kinetic trap,” based on our studies of the
retinitis pigmentosa mutant D190N (31). Our current results
highlight the instability of the ATR–opsin covalent bond and
bolster this hypothesis. They also imply that exchange of the dark-
state 11CR chromophore should be possible if the “trap” is bro-
ken, an event that has been observed for cone opsins (32).
Opsin Can Transiently Retain an Active-Like Conformation Following
Agonist Dissociation. Implicit in both the discussion above and the
conformational selection model (Fig. 1) is the concept that ATR
release and the reversion of Ops* to Ops are sequential, but distinct,
events. Our results simultaneously monitoring the Ops* conformation
and ATR release support this idea, showing the decay of Ops* can
lag behind agonist dissociation (Fig. 5A). Accelerating the release
further exaggerates the disparity (Fig. 5 C and E).
At 37 °C, the time lag for “WT” rhodopsin (V139W/V250B) is
∼1 min (extrapolated from the Arrhenius value). Although this
value is significantly longer than the subsecond lifetimes recently
estimated for some B2AR conformations (33), and is likely exag-
gerated by our nonphysiological conditions, it is reminiscent of the
slow movements induced in the B2AR upon binding of some ag-
onists (34), ascribed to a sequence of conformational changes these
ligands induce upon binding and activating the receptor. Perhaps
the time lag we observe reflects a similar process, in reverse. Re-
gardless, our data do clearly show that aspects of the active con-
formation can persist even in the absence of bound agonist.
This time lag between agonist release and collapse of Ops* is
intriguing. Retinal-free rhodopsin (Ops) is extremely inactive,
showing very little constitutive activity (5), and hence is normally
assumed to only exist as an inactive conformation (4). How, then,
could an empty, active-like receptor conformation transiently
persist following activation? Presumably, this reflects some sort
of “protein memory,” where the photoreceptor briefly stays ac-
tive-like in the absence of the agonist.
Such persistence of protein memory might also play a role in
signal amplification by other GPCRs. Conformational selection-
based ligand-binding mechanisms as well as multiple receptor
signaling states are well documented for other GPCRs, including
the B2AR and CB1 receptor (7, 20, 35–38). Hence, the delayed
reversion to the inactive receptor conformation we observe for
rhodopsin might play a heretofore unappreciated role here and
in other GPCR signaling systems.
Implications for Other Visual GPCRs.Our results also have interesting
implications for the cone opsins responsible for color vision. Re-
cently, Knox and coworkers (39) showed that the process of ATR
release from cone opsins is faster than rhodopsin but exhibits the
same activation energy, and thus concluded both photoreceptors
share a similar mechanism of activation for Schiff base hydrolysis,
with the differences in release rates indicating different non-
covalent interactions between the retinal and the binding pocket.
Our data are consistent with this idea.
Moreover, our results might also help explain other differ-
ences between rhodopsin and cone opsins. Cone opsins operate
in high-light conditions and thus have to rapidly respond to new
photons without losing sensitivity. Therefore, their faster re-
covery to the inactive state (25, 40, 41), due to a rapid collapse to
an inactive (Ops) conformation, would discourage ATR rebinding
(and thus persistence of signaling) and be essential for maintaining
the ability to discriminate differences in light intensity during
daylight conditions (25). In contrast, rhodopsin, the dim-light
photoreceptor, needs to convert a single photon into a maximal
neuronal signal. Thus, opsin lingering in an active conformation
after agonist release, and thus possibly activating more G proteins,
would not be detrimental and may act to facilitate kinase or
arrestin binding.
Conclusions
Our data provide further evidence that rhodopsin behaves like a
ligand-binding GPCR. Despite the uniqueness of its covalently
bound ligand, rhodopsin seems to interact with its retinal li-
gands in a way consistent with a conformational selection model
(8), opening the possibility of using pharmacological approaches
to modulate the activity of this key photoreceptor. Currently,
drugs targeting rhodopsin only seek to improve receptor biogenesis.
However, our data suggest that it may be possible to develop drugs
that target and competitively displace ATR causing inappropriate
signaling. Replacing the ATR with a less efficacious ligand could be
used to quell inappropriate signaling and promote the deactivation
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of the photoreceptors, thereby improving general visual sensitivity
in some cases.
Experimental Procedures
Buffers, Cloning, Mutagenesis, Transfection, and Purification of Rhodopsin
Mutants. Site-directed mutagenesis was carried out by overlap extension PCR
into a rhodopsin background containing minimal reactive cysteines (17).
Opsin experiments contained a stabilizing disulfide (N2C/D282C) to facilitate
apoprotein purification (42). Proteins were expressed by transient trans-
fection in COS-1 cells and either purified as opsin or regenerated with 11CR
and labeled with the fluorophore monobromobimane as previously de-
scribed (8, 15). See SI Experimental Procedures for full details.
Fluorescent Measurements. Fluorescence spectroscopy was carried out as
previously described using a modified Photon Technology International
steady-state fluorometer with the excitation source replaced with OceanOptics
LEDs, LLS-295 and LLS-405 (8, 13). A bifurcated fiber optic cable allowed for
dual excitation of both intrinsic tryptophans and a bimane probe. See SI Ex-
perimental Procedures for full details.
Radioligand Binding. Labeled ATR exchange was done by photoactivating
regenerated opsins in the presence of exogenous [3H]ATR. Unbound radio-
labeled retinals were removed using mini size-exclusion chromatography
columns and the incorporated [3H]ATR was counted by liquid scintillation
(43). See SI Experimental Procedures for full details.
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